Risk factors and management of iatrogenic colorectal perforation in diagnostic colonoscopy: a single-center cohort study
CONCLUSIONS: Additional precautions are required to prevent perforation in elderly patients, hospital settings, low BMI, sedated patients, or by a doctor with slight familiarity with endoscopies (but still insufficient experience). Endoscopic treatment should be actively considered if diagnosis is prompt, abdominal pain absent, and especially the rectal perforation is present.PMID:38380637 | DOI:10.1080/00365521.2024.2316766 (Source: Scandinavian Journal of Gastroenterology)
Source: Scandinavian Journal of Gastroenterology - February 21, 2024 Category: Gastroenterology Authors: Aryoung Kim Heejung Kim Eun Ran Kim Ji Eun Kim Sung Noh Hong Dong Kyung Chang Young-Ho Kim Source Type: research

Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma
CONCLUSION: In patients with inoperable advanced or locally advanced ESCC, peripheral blood PIV, SII, and NLR have predictive value for immunotherapy outcome, SII is an independent risk factor affecting the survival prognosis, and SII ≥834.295 suggests a poor prognosis from immunotherapy.PMID:38362884 | DOI:10.1080/00365521.2024.2319319 (Source: Scandinavian Journal of Gastroenterology)
Source: Scandinavian Journal of Gastroenterology - February 16, 2024 Category: Gastroenterology Authors: Maodong Fu Zhiyong Li Jun Ma Feng Shen Xiuping Zhang Source Type: research

Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study
CONCLUSIONS: Dietary intakes in newly diagnosed IBD patients were mostly in line with Nordic Nutrition Recommendations. Higher proportion of IBD patients exceeded recommended allowances of fat and added sugar than the comparison sample. Insufficient micronutrient intake, anemia and hypoalbuminemia are present challenges in IBD patients that require monitoring.PMID:38356408 | DOI:10.1080/00365521.2024.2313056 (Source: Scandinavian Journal of Gastroenterology)
Source: Scandinavian Journal of Gastroenterology - February 15, 2024 Category: Gastroenterology Authors: Insaf Zerouga J ørgen Valeur Christine Sommer Milada Cvancarova Sm åstuen Asle Wilhelm Medhus Charlotte Lund Ingunn Johansen Raziye Boyar Cetinkaya May-Bente Bengtson Roald Torp Øistein Hovde Gert Huppertz-Hauss Trond Espen Detlie Tone Bergene Aabrekk Source Type: research

The lncRNA TRG-AS1 promotes the growth of colorectal cancer cells through the regulation of P2RY10/GNA13
CONCLUSIONS: TRG-AS1 knockdown repressed the growth of HT-29 and LoVo by regulating P2RY10 and GNA13 expression.PMID:38357893 | DOI:10.1080/00365521.2024.2318363 (Source: Scandinavian Journal of Gastroenterology)
Source: Scandinavian Journal of Gastroenterology - February 15, 2024 Category: Gastroenterology Authors: Longqing Shi Baoyang Luo Linghui Deng Qi Zhang Yuanjiu Li Donglin Sun Hua Zhang Lin Zhuang Source Type: research

Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study
CONCLUSIONS: Dietary intakes in newly diagnosed IBD patients were mostly in line with Nordic Nutrition Recommendations. Higher proportion of IBD patients exceeded recommended allowances of fat and added sugar than the comparison sample. Insufficient micronutrient intake, anemia and hypoalbuminemia are present challenges in IBD patients that require monitoring.PMID:38356408 | DOI:10.1080/00365521.2024.2313056 (Source: Scandinavian Journal of Gastroenterology)
Source: Scandinavian Journal of Gastroenterology - February 15, 2024 Category: Gastroenterology Authors: Insaf Zerouga J ørgen Valeur Christine Sommer Milada Cvancarova Sm åstuen Asle Wilhelm Medhus Charlotte Lund Ingunn Johansen Raziye Boyar Cetinkaya May-Bente Bengtson Roald Torp Øistein Hovde Gert Huppertz-Hauss Trond Espen Detlie Tone Bergene Aabrekk Source Type: research

The lncRNA TRG-AS1 promotes the growth of colorectal cancer cells through the regulation of P2RY10/GNA13
CONCLUSIONS: TRG-AS1 knockdown repressed the growth of HT-29 and LoVo by regulating P2RY10 and GNA13 expression.PMID:38357893 | DOI:10.1080/00365521.2024.2318363 (Source: Scandinavian Journal of Gastroenterology)
Source: Scandinavian Journal of Gastroenterology - February 15, 2024 Category: Gastroenterology Authors: Longqing Shi Baoyang Luo Linghui Deng Qi Zhang Yuanjiu Li Donglin Sun Hua Zhang Lin Zhuang Source Type: research

Gastrointestinal cancer precursor risk and mortality in pancreatic intraductal papillary mucinous neoplasms: a nationwide cohort study
CONCLUSIONS: We found no association between IPMN and other GI cancer precursors. This argues against comprehensive routine surveillance for other GI cancer precursors in IPMN patients. Mortality was increased in IPMN with pancreatic cancer being the most common cause of death, indicating the need for lifelong follow up in all resected and non-resected patients with IPMN. However, results should be confirmed in larger cohorts.PMID:38351653 | DOI:10.1080/00365521.2024.2310162 (Source: Scandinavian Journal of Gastroenterology)
Source: Scandinavian Journal of Gastroenterology - February 14, 2024 Category: Gastroenterology Authors: Miroslav Vujasinovic Peter Elbe Isabella Ekheden Qiao-Li Wang Marcus Thuresson Bjorn Roelstraete Sam Ghazi J-Matthias L öhr Jonas F Ludvigsson Source Type: research

Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative
CONCLUSION: IFX desensitization in patients with IBD is a safe therapeutic alternative and represents a potential option for patients refractory to multiple biologics.What is already known? Hypersensitivity reactions to the administration of infliximab is frequent. Occurrence of hypersensitivity reaction, either immediate or delayed, usually leads to permanent drug discontinuation.What is new here? Infliximab desensitization is well tolerated with no hypersensitivity reaction recurrence in 70% of patients. Clinical success at 6 months was of 48% and around a third of patients remained under infliximab therapy two years aft...
Source: Scandinavian Journal of Gastroenterology - February 14, 2024 Category: Gastroenterology Authors: Nassim Hammoudi D éborah Hassid Jo ëlle Bonnet My-Linh Tran Minh Clotilde Baudry Anne Vauthier Leila Chedouba Pascal Houz é Nelson Lourenco Thomas Aparicio Jean-Marc Gornet Matthieu Allez Source Type: research